tirzepatide high blood pressure and reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial Tirzepatide and Blood Pressure Meds:

Administered through injections, it targets multiple pathways to help manage weight effectively

The results of all sensitivity and scenario analyses provide consistent cost-effectiveness estimates below a commonly considered threshold of 357,000 DKK (around 50,000) per QALY [53,54,55]

The lower panel is arranged based on the mean of the absolute SHAP values for each variable, where individual values with large impact in a specific participant can influence the mean for that particular variable, while the variable across all participants may be of less relative importance

For the efficacy estimandi, at 52 weeks, tirzepatide led to a mean apnea-hypopnea index (AHI) reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events per hour for placebo

But here is where retatrutide diverges